申请人:MERCK FROSST CANADA INC.
公开号:EP0166591A2
公开(公告)日:1986-01-02
Compounds of the formula I
where
R1 is H or alkyl of 1 to 6 carbons or R1 and R8 taken together form a group (CH2)v wherein v is 1 to 7;
R2 is
where
each R8 is independently H, OH, C1 to C4-O-alkyl or alkyl of 1 to 4 carbons; or an R1 and an R8 taken together form a group (CH2)v wherein v is 1 to 7,
R9 is COOR1; CH2OH; CHO; tetrazole; NHSO2R10 wherein R10 is OH, alkyl or alkoxy of 1 to 6 carbons, perhaloalkyl of 1 to 6 carbons, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbons, halogen, hydroxy, COOH, CN, formyl or acyl of 1 to 6 carbons; CONHSO2R10; hydroxymethylketone; CN; or CON(R8)2;
X is O; S; SO; S02; NR11 wherein R11 is H, alkyl of 1 to 6 carbons, acyl of 1 to 6 carbons, CN; CR1R8;
or the unit
wherein the dotted line represents an optical triple bond and in which the R1 and R8 substituents are absent when a triple bond is present;
r and q are each independently 0 to 5 and p is 0 or 1 provided that the total of p, q and r is 2 to 6;
R3 is H, alkyl of 1 to 6 carbons; phenyl or phenyl substituted by R4; or C1 to C4 alkylphenyl or C1 to C4 alkylphenyl in which the phenyl is substituted by R4;
R4, R5, R6 and R7 are each independently selected from:
(1) hydrogen;
(2) alkyl having 1 to 6 carbon atoms;
(3) alkenyl having 2 to 6 carbon atoms;
(4) -(CH2)nM
wherein n is 0 to 3 and M is
a) OR12;
b) halogen;
c) CF3;
d) SR12;
e) phenyl or substituted phenyl wherein substituted phenyl is as defined below in the definition of R12;
f) COOR13;
g)
h) tetrazole;
i)
wherein R15 is C1 to C6 alkyl, benzyl or phenyl;
j) -NR13R13;
k) -NHSO2R16 wherein R16 is C1 to C6 alkyl, phenyl, or CF3;
I)
m) -SOR12;
n) -CON13R13;
o) -SO2NR13R13;
p) -SO2R12;
q) N02;
r)
s)
t)
u) CN;
each R12 independently is H; C1 to C6 alkyl; benzyl; phenyl or substituted phenyl wherein the substituents are C1 to C3 alkyl, halogen, CN, CF3, COOR13, CH2COOR13, C1 to C3 alkoxy, or C1 to C4 perfluoroalkyl;
each R13 is independently H, phenyl or C1 to C6 alkyl; and,
each R14 independently is H, (CH2)nCOOR13 wherein n is 0 to 4, C1 to C6 alkyl, CF3, phenyl, or substituted phenyl wherein substituted phenyl is as defined above in the definition of R12;
and their pharmaceutically acceptable salts are useful as prostaglandin antagonists and are made into pharmaceutical compositions. Certain of the compounds are novel.
式 I 的化合物
式中
R1 是 H 或 1 至 6 个碳原子的烷基,或 R1 和 R8 共同组成一个基团 (CH2)v,其中 v 为 1 至 7;
R2 是
其中
每个 R8 独立地为 H、OH、C1 至 C4-O 烷基或 1 至 4 碳原子的烷基;或一个 R1 和一个 R8 共同形成一个基团 (CH2)v,其中 v 为 1 至 7、
R9 是 COOR1;CH2OH;CHO;四唑;NHSO2R10,其中 R10 是 OH、1-6 碳原子的烷基或烷氧基、1-6 碳原子的全卤代烷基、苯基或被 1-3 碳原子的烷基或烷氧基取代的苯基、卤素、羟基、COOH、CN、1-6 碳原子的甲酰基或酰基;CONHSO2R10;羟甲基酮;CN 或 CON(R8)2;
X 是 O;S;SO;S02;NR11,其中 R11 是 H、1-6 碳原子的烷基、1-6 碳原子的酰基、CN;CR1R8;
或单元
其中虚线代表光学三键,当存在三键时,R1 和 R8 取代基不存在;
r 和 q 各自独立地为 0 至 5,p 为 0 或 1,条件是 p、q 和 r 的总和为 2 至 6;
R3 是 H、1 至 6 碳原子的烷基;苯基或被 R4 取代的苯基;或 C1 至 C4 烷基苯基或苯基被 R4 取代的 C1 至 C4 烷基苯基;
R4、R5、R6 和 R7 各自独立地选自以下各项:
(1) 氢
(2) 具有 1 至 6 个碳原子的烷基
(3) 具有 2 至 6 个碳原子的烯基;
(4) -(CH2)nM
其中 n 为 0 至 3,M 为
a) OR12
b) 卤素
c) CF3
d) SR12
e) 苯基或取代苯基,其中取代苯基的定义见下文 R12 的定义;
f) COOR13
g)
h) 四氮唑
i)
其中 R15 为 C1 至 C6 烷基、苄基或苯基;
j) -NR13R13
k) -NHSO2R16 其中 R16 是 C1 至 C6 烷基、苯基或 CF3;
I)
m) -SOR12
n) -CON13R13
o) -SO2NR13R13;
p) -SO2R12
q) N02;
r)
s)
t)
u) CN;
每个 R12 独立地为 H、C1-C6 烷基、苄基、苯基或取代苯基,其中取代基为 C1-C3 烷基、卤素、CN、CF3、COOR13、CH2COOR13、C1-C3 烷氧基或 C1-C4 全氟烷基;
每个 R13 独立地是 H、苯基或 C1 至 C6 烷基;以及
每个 R14 独立地是 H、(CH2)nCOOR13(其中 n 为 0 至 4)、C1 至 C6 烷基、CF3、苯基或取代的苯基(其中取代的苯基如上文 R12 定义中所定义);
及其药学上可接受的盐类可用作前列腺素拮抗剂并制成药物组合物。某些化合物是新型的。